Carol A. Langford, MD, MHS, FACP
Disclosures
Langford reports no relevant financial disclosures.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Monitoring, I think is in many ways one of the most important things that we do, because what we're looking for as far as is to see how is the disease doing as far as And when we talk about we're trying to determine the disease activity, which would be inflammation that is, causing organ injury. So we're trying to see is there evidence of ongoing disease activity? Do we think that it has gone into a period of quiescence or remission? So monitoring is an important part of that. We're also looking to see if there's evidence as far as side effects that are occurring as a result of treatment. And again, we may also see other features emerging such as, you know, other diseases that can be occurring.
